NAFLD trial enrolls patients to assess effect of Basis on metabolic factors

Elysium Health completed enrollment for a clinical trial designed to evaluate the efficacy of Basis, a combination of the company’s proprietary nicotinamide riboside and pterostilbene, on liver fat accumulation in adults with nonalcoholic fatty liver disease, according to a press release.The formulation of Basis was designed to increase oxidized nicotinamide adenine dinucleotide (NAD+) levels — a cofactor central to metabolism — and activate NAD-dependent sirtuins, which also regulate important physiological processes like lipid metabolism.“There is evidence to showRead More

Share on facebook
Share on twitter
Share on linkedin